IQGAP3 is relevant to prostate cancer - A detailed presentation of potential pathomechanisms

Sep 24, 2026

Investigation of IQGAP3’s oncogenic actions in prostate cancer (PC) links its expression to tumor progression, metastasis, and p53 mutation. IQGAP3 expression in PC was assessed by immunohistochemistry and multiple datasets, followed by network pathway analysis and construction of a multigene signature (SigIQGAP3NW). The signature robustly predicts recurrence and poor prognosis across independent PC cohorts and 26 cancer types, and associates with mitosis-related genes, immune checkpoint evasion, Treg infiltration, and reduced response to immune checkpoint blockade.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Introduction

Methods

Expression analysis and immunohistochemistry

Network analysis and multigene signature construction

Results

Association with tumor progression and p53 mutation

Correlation with PLK1 and TOP2A

Prognostic performance of SigIQGAP3NW

Links to immune evasion and checkpoint blockade response

Conclusions

Journal of Advanced Research 54 (2023) 195–210 Contents lists available at ScienceDirect Journal of Advanced Research journal [homepage: www. elsevier. com/locate/jare](homepage: www. elsevier. com/locate/jare) Original Article IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms Wenjuan Mei a,b,c,d, ⇑, Ying Dong b,c,d, Yan Gub,c,d, Anil Kapoor b,c,d, Xiaozeng Lin b,c,d, Yingying Sub,c,d, Sandra Vega Neirab,c,d, Damu Tang b,c,d, ⇑ a Department of Nephrology, The First Afﬁliated Hospital of Nanchang University, Jiangxi, China b Urological Cancer Center for Research and Innovation (UCCRI), St Joseph’s Hospital, Hamilton, ON L8N 4A6, Canada c Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada d The Research Institute of St Joe’s Hamilton, St Joseph’s Hospital, Hamilton, ON L8N 4A6, Canada h i g h l i g h t s 􀀁 IQGAP3 network (NW) regulates mitosis in prostate cancer (PC) and other cancers. 􀀁 IQGAP3 correlates with PLK1 and TOP2A expression in PC and other cancers. 􀀁 SigIQGAP3NW robustly predicts recurrence and poor prognosis in PC and other cancers. 􀀁 RELT signiﬁcantly correlates with immune checkpoint in PC and across human cancers. 􀀁 SigQIGAP3NW and RELT predict cancer resistance to immune checkpoint blockage therapy. g r a p h i c a l a b s t r a c t a r t i c l e i n f o Article history: Received 30 October 2022 Revised 12 December 2022 Accepted 15 January 2023 Available online 18 January 2023 Keywords: IQGAP3 Prostate cancer Clinical relevance Prognostic prediction Overall survival Immune checkpoint blockade therapy a b s t r a c t Introduction: IQGAP3 possesses oncogenic actions; its impact on prostate cancer (PC) remains unclear. Objective: We will investigate IQGAP30 s association with PC progression, key mechanisms, prognosis, and immune evasion. Methods: IQGAP3 expression in PC was examined by immunohistochemistry and using multiple datasets. IQGAP3 network was analyzed for pathway alterations and used to construct a multigene signature (SigIQGAP3NW). SigIQGAP3NW was characterized using LNCaP cell-derived castration-resistant PCs (CRPCs), analyzed for prognostic value in 26 human cancer types, and studied for association with immune evasion. Results: Increases in IQGAP3 expression associated with PC tumorigenesis, tumor grade, metastasis, and p53 mutation. IQGAP3 correlative genes were dominantly involved in mitosis. IQGAP3 correlated with PLK1 and TOP2A expression at Spearman correlation/R = 0.89 (p 􀀃 3.069e-169). Both correlations were enriched in advanced PCs and Taxane-treated CRPCs and occurred at high levels (R > 0.8) in multiple cancer types. SigIQGAP3NW effectively predicted cancer recurrence and poor prognosis in independent PC cohorts and across 26 cancer types. SigIQGAP3NW stratiﬁed PC recurrence after adjustment for age at diagnosis, grade, stage, and surgical margin. SigIQGAP3NW component genes were upregulated in PC, metastasis, LNCaP cell-produced CRPC, and showed an association with p53 mutation. SigIQGAP3NW Peer review under responsibility of Cairo University. ⇑ Corresponding authors at: Department of Nephrology, The First Afﬁliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China (W. Mei). T3310, St. Joseph’s Hospital, 50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada (D. Tang). E-mail [addresses:](addresses: wenjuanmei1986@163.com)[ wenjuanmei1986@163.com](addresses: wenjuanmei1986@163.com) (W. Mei), [damut@mcmaster.ca](damut@mcmaster.ca) (D. Tang). [https://doi.org/10.1016/j.jare.2023.01.015](https://doi.org/10.1016/j.jare.2023.01.015) 2090-1232/􀀁 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)). W. Mei, Y. Dong, Y. Gu et al. Journal of Advanced Research 54 (2023) 1

FAQs

What was the study’s main objective regarding IQGAP3 and prostate cancer?

To examine IQGAP3’s association with prostate cancer progression, key mechanisms, prognosis, and immune evasion.

How did the researchers evaluate IQGAP3 in prostate cancer?

They analyzed IQGAP3 expression using immunohistochemistry and multiple datasets, then studied the IQGAP3 network for pathway alterations and built a multigene signature (SigIQGAP3NW).

What do SigIQGAP3NW and RELT indicate for prognosis and immune checkpoint blockade therapy?

SigIQGAP3NW predicts cancer recurrence and poor prognosis, while RELT correlates with immune checkpoints and both SigIQGAP3NW and/or RELT predict resistance to immune checkpoint blockade therapy.

Sep 24, 2026

Uploaded by Well Done